Pfizer reports positive phase 3 ELREXFIO myeloma data

Pfizer said on April 29, 2026, that its phase 3 MagnetisMM-5 trial met the primary endpoint for ELREXFIO (elranatamab) in adults with relapsed or refractory multiple myeloma who had received at least one prior line of therapy. According to the company, elranatamab monotherapy significantly improved progression-free survival versus daratumumab, pomalidomide, and dexamethasone, exceeding the prespecified interim efficacy threshold. Overall survival data weren't mature at the interim readout, and Pfizer said it plans to discuss the results with global regulators and present detailed findings at a future medical meeting. (pfizer.com)

Why it matters: For veterinary professionals tracking the broader oncology market, this is another sign that bispecific antibodies are continuing to move earlier in treatment lines, not just later-stage salvage use. ELREXFIO already has accelerated FDA approval in the U.S. for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy, and a positive phase 3 study in a less heavily pretreated population could support label expansion. Safety remains central: the current U.S. label carries boxed warnings for cytokine release syndrome and neurologic toxicity, and prior MagnetisMM-3 data showed substantial rates of infections, cytopenias, and treatment interruptions. (pfizer.com)

What to watch: Watch for full MagnetisMM-5 data, including hazard ratio details, adverse-event findings, and any regulatory submission timeline Pfizer provides. (pfizer.com)